Anesthetic Effect - Pipeline Review, H1 2020

Global Markets Direct
97 Pages - GMD18206
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H1 2020, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 1, 4, 1, 12, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

'

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anesthetic Effect - Overview
Anesthetic Effect - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anesthetic Effect - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anesthetic Effect - Companies Involved in Therapeutics Development
Andros Pharmaceuticals Co Ltd
Avecho Biotechnology Ltd
Baudax Bio Inc
Biotts SA
Crescita Therapeutics Inc
Cuda Pharmaceuticals LLC
Drawbridge Pharmaceuticals Pty Ltd
Expanesthetics Inc
Hangzhou Adamerck Pharmlabs Inc
Hefei Cosource Pharmaceutical Inc
Jiangsu Hengrui Medicine Co Ltd
Lannett Co Inc
Lee's Pharmaceutical Holdings Ltd
LipoSeuticals Inc
MedinCell SA
NutriBand Inc
Paion AG
Physica Pharma
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
Sphaera Pharma Pte Ltd
Yichang Humanwell Pharmaceutical Co Ltd
Anesthetic Effect - Drug Profiles
(lidocaine + tetracaine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alphaxalone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aom-0498 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aom-0765 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APC-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclopentol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cysteine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXPS-09 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fospropofol disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HR-7056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HYRPB-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KL-100137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
morphine glucuronide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTCA-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHY-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propofol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remimazolam besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropivacaine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block NaV1.7 for Local Anesthetic Effect - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NMDA Receptor for Anaesthesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPR-819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Anesthetic Effect - Dormant Projects
Anesthetic Effect - Discontinued Products
Anesthetic Effect - Product Development Milestones
Featured News & Press Releases
Mar 12, 2020: Acacia Pharma announces brief extension of FDA review period for NDA for BYFAVO
Jan 23, 2020: PAION : Mundipharma receives market approval for Anerem (Remimazolam) in general anesthesia in Japan
Jan 13, 2020: Lannett announces FDA approval of NDA for branded anesthetic product, Cocaine Hydrochloride nasal solution 4%
Dec 30, 2019: Paion announces submission of new drug application for remimazolam by its licensee Hana Pharm in South Korea
Nov 20, 2019: Paion announces submission of the marketing authorization application for Remimazolam in procedural sedation to the European Medicines Agency
Jul 16, 2019: United States Patent and Trademark Office issues U.S. patent covering an enhanced formulation of Pliaglis
Jun 28, 2019: EIB and German specialty pharmaceutical company PAION AG have signed a €20 million loan agreement
Jun 11, 2019: Hana Pharm presented clinical trial results of Remimazolam at International Congress of Cardiothoracic and Vascular Anesthesia
Jun 10, 2019: FDA accepts filing of NDA for Remimazolam
Apr 09, 2019: Cosmo Pharmaceuticals announces submission of Remimazolam NDA to FDA
Nov 06, 2018: R-Pharm Group and Paion announce successful completion of remimazolam phase III clinical trial
Oct 08, 2018: PAION announces clinical development progress with Remimazolam by its partner Hana Pharm in South Korea
Jul 24, 2018: PAION starts EU Phase III trial with remimazolam in general anesthesia
May 17, 2018: Paion announces clinical development progress with Remimazolam by its partner R-Pharm in Russia
Apr 30, 2018: Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anesthetic Effect, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Anesthetic Effect - Pipeline by Andros Pharmaceuticals Co Ltd, H1 2020
Anesthetic Effect - Pipeline by Avecho Biotechnology Ltd, H1 2020
Anesthetic Effect - Pipeline by Baudax Bio Inc, H1 2020
Anesthetic Effect - Pipeline by Biotts SA, H1 2020
Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H1 2020
Anesthetic Effect - Pipeline by Cuda Pharmaceuticals LLC, H1 2020
Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2020
Anesthetic Effect - Pipeline by Expanesthetics Inc, H1 2020
Anesthetic Effect - Pipeline by Hangzhou Adamerck Pharmlabs Inc, H1 2020
Anesthetic Effect - Pipeline by Hefei Cosource Pharmaceutical Inc, H1 2020
Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Anesthetic Effect - Pipeline by Lannett Co Inc, H1 2020
Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
Anesthetic Effect - Pipeline by LipoSeuticals Inc, H1 2020
Anesthetic Effect - Pipeline by MedinCell SA, H1 2020
Anesthetic Effect - Pipeline by NutriBand Inc, H1 2020
Anesthetic Effect - Pipeline by Paion AG, H1 2020
Anesthetic Effect - Pipeline by Physica Pharma, H1 2020
Anesthetic Effect - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, H1 2020
Anesthetic Effect - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H1 2020
Anesthetic Effect - Pipeline by SiteOne Therapeutics Inc, H1 2020
Anesthetic Effect - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
Anesthetic Effect - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020
Anesthetic Effect - Dormant Projects, H1 2020
Anesthetic Effect - Dormant Projects, H1 2020 (Contd..1), H1 2020
Anesthetic Effect - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Anesthetic Effect, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

[email protected]
+1 212 564 2838

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

[email protected]
+1 212 564 2838

Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838